Inotiv (STU:BS50) Debt-to-Equity : 1.69 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Inotiv Debt-to-Equity?

Inotiv's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €17.9 Mil. Inotiv's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €375.1 Mil. Inotiv's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €233.1 Mil. Inotiv's debt to equity for the quarter that ended in Dec. 2023 was 1.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Inotiv's Debt-to-Equity or its related term are showing as below:

STU:BS50' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.44 Med: 0.64 Max: 4.98
Current: 1.69

During the past 13 years, the highest Debt-to-Equity Ratio of Inotiv was 4.98. The lowest was 0.44. And the median was 0.64.

STU:BS50's Debt-to-Equity is ranked worse than
91.79% of 195 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs STU:BS50: 1.69

Inotiv Debt-to-Equity Historical Data

The historical data trend for Inotiv's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Debt-to-Equity Chart

Inotiv Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

1.55

4.79

1.66

1.07

1.55

Inotiv Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.45	1.52	1.52	1.55	1.69

Competitive Comparison of Inotiv's Debt-to-Equity

For the Diagnostics & Research subindustry, Inotiv's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Inotiv's Debt-to-Equity falls into.

Inotiv Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Inotiv's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.083	+	374.246)	/	252.197
	=	1.55

Inotiv's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.896	+	375.058)	/	233.067
	=	1.69

Inotiv (STU:BS50) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Inotiv Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Inotiv's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (STU:BS50) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Debt-to-Equity

Comparable Companies

STIM FONR BNR ACRS PRPH VNRX MDXH BDSX BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

NOTV:USA

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines